← All trials
NCT02132767
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2014
- Primary completion
- Sep 1, 2015
- Completion date
- Sep 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 523
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Icahn School of Medicine at Mount SinaiLead sponsor
- Cardiothoracic Surgical Trials NetworkStudy chair
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- National Institute of Neurological Disorders and Stroke (NINDS)Collaborator
- Canadian Institutes of Health Research (CIHR)Collaborator
- Icahn School of Medicine at Mount SinaiReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.